Pamidronat Onkovis (Pamidronate Disodium)

Pamidronate binds to hydroxyapatite at active bone‑resorption sites. When osteoclasts attach, the drug is taken up and blocks the enzyme farnesyl‑pyrophosphate synthase in the mevalonate pathway, which impairs osteoclast maturation and reduces bone resorption, leading to lower serum calcium.

The dose of Pamidronat Onkovis is determined by the prescribing clinician based on the specific indication, patient weight, renal function and laboratory values. Healthcare professionals set the infusion rate and total amount according to established clinical guidelines.

Pamidronate is classified as contraindicated in pregnancy unless the potential benefit justifies the risk to the fetus. It is also not recommended while breastfeeding because it may be excreted in milk. Women of child‑bearing potential should use effective contraception during treatment.

To request Pamidronat Onkovis, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Pamidronate is similar to other bis‑bisphosphonates such as zoledronic acid in its mechanism of inhibiting osteoclast‑mediated bone resorption, but it differs in potency, dosing frequency and renal safety profile. Clinicians may choose pamidronate when a less potent agent or a specific infusion schedule is preferred.

Pamidronat Onkovis should be stored at ambient temperature, below 25 °C, in its original packaging. The container should be protected from direct light and moisture to maintain drug stability until the time of use.

The product is supplied as a sterile powder that is reconstituted with a suitable diluent and given by intravenous infusion. Administration is performed by qualified healthcare personnel in a clinical setting, following aseptic technique and recommended infusion rates.

Serious adverse events include acute renal failure, severe hypocalcaemia, osteonecrosis of the jaw and atypical femoral fractures. Patients should be monitored for changes in renal function, calcium levels and any oral symptoms throughout treatment.

Pamidronat Onkovis is contraindicated in patients with known hypersensitivity to pamidronate or any excipients, those with severe renal impairment (creatinine clearance <30 mL/min), and individuals with untreated hypocalcaemia. Caution is also advised for patients with active dental disease.